Answers are grounded in this paper and cite their sources.
FDA evaluates GLP-1 medications and finds no increased risk of suicidal behaviors, suggesting manufacturers update labels.
The Food and Drug Administration (FDA) has requested that manufacturers of some Glucagon‐Like Peptide‐1 Receptor Agonists (GLP‐1 R A) remove warnings about suicidal behavior and ideation from labels. The request in a January 13, 2026 letter is an “update” on the FDA's ongoing evaluation of this issue. In the January letter, the FDA stated that it “did not identify an increased risk of suicidal ideation or behavior with the use of GLP‐1 RA medications.” Below is the public information from the letter.
No takes yet. Share an insight, caveat, or question.
A 2026 study studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: